Literature DB >> 27497260

Patient and general public preferences for health states: A call to reconsider current guidelines.

M M Versteegh1, W B F Brouwer2.   

Abstract

In economic evaluations of health care interventions, benefits are often expressed in terms of Quality-Adjusted Life-Years (QALYs). The QALY comprises length and quality of life into one measure which allows cross-disease comparability. The quality adjustment of the QALY is based on preferences for health states. An important normative choice is the question whose preferences for states of health we wish to capture. The answer to this question is directly related to the normative question regarding the appropriate maximand in health care decisions. Currently, preferences are commonly derived from the general public, rather than from actual patients. This choice, which can have large consequences on final outcomes of economic evaluations, has always been a topic of debate. This paper clarifies and furthers the discussion regarding the appropriate source of preferences for health state valuations, acknowledges the plurality of different perspectives, and argues that health economic guidelines could require analysis of benefit in terms of QALYs based on both patient and general public preferences.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adaptation; Cost utility analysis; Health economics; Patient preferences; Public preferences; QALY; Societal perspective

Mesh:

Year:  2016        PMID: 27497260     DOI: 10.1016/j.socscimed.2016.07.043

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  42 in total

Review 1.  Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research.

Authors:  Patricia Cubi-Molla; Koonal Shah; Kristina Burström
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

2.  The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment.

Authors:  Renske J Hoefman; Job van Exel; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

3.  Evaluating science communication.

Authors:  Baruch Fischhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-26       Impact factor: 11.205

4.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

5.  Giving a Voice to Marginalised Groups for Health Care Decision Making.

Authors:  Richard De Abreu Lourenço; Nancy Devlin; Kirsten Howard; Jason J Ong; Julie Ratcliffe; Jo Watson; Esther Willing; Elisabeth Huynh
Journal:  Patient       Date:  2020-10-01       Impact factor: 3.883

6.  Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Authors:  David John Mott
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

7.  What should we know about the person behind a TTO?

Authors:  Floortje van Nooten; Jan Busschbach; Michel van Agthoven; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2018-12

8.  Exclusion Criteria as Measurements I: Identifying Invalid Responses.

Authors:  Barry Dewitt; Baruch Fischhoff; Alexander L Davis; Stephen B Broomell; Mark S Roberts; Janel Hanmer
Journal:  Med Decis Making       Date:  2019-08-28       Impact factor: 2.583

9.  The impact of depression on health-related quality of life and wellbeing: identifying important dimensions and assessing their inclusion in multi-attribute utility instruments.

Authors:  Lidia Engel; Gang Chen; Jeffrey Richardson; Cathrine Mihalopoulos
Journal:  Qual Life Res       Date:  2018-07-13       Impact factor: 4.147

Review 10.  Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?

Authors:  Donna Rowen; Oliver Rivero-Arias; Nancy Devlin; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2020-04       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.